CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB006

Prostate Specific Antigen Testing

BCBSOK reimbursement and lab management criteria for PSA testing, including screening, repeat testing intervals, percent free PSA use, diagnostic and monitoring indications; applies to providers submitting claims to Blue Cross Blue Shield of Oklahoma.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyProstate Specific Antigen Testing

Policy CodePolicy CPCPLAB006

Change TypeRemoved, Clarified, Revised

Effective DateSep 5, 2025

Next Review Date

Key ActionSubmit accurate documentation and claims using valid HIPAA-approved code sets; claims may be subject to review and require additional documentation upon request.

SourceLink

POLICY UPDATE CHANGES

Removed #3 from Reimbursement Information.

Edited items 3c and 4b to replace 'little to no comorbidities' with a parenthetical reference to Note 1.

Document updated with literature review and references revised.

annualrecommended maximum screening frequency for men >=50

40-50 yrsmay be reimbursable annually

<1 ng/mlrepeat screening interval 2-4 years

1-3 ng/mlrepeat screening interval 1-2 years

Percent free PSAnot reimbursable as first-line screening

PSA Testing Coverage Criteria

PSA testing coverage criteria

Reimbursable and non-reimbursable uses of total PSA and percent free PSA are specified below.

ALL of the following

Total PSA screening may be reimbursable at least once per year for men 50 years or older.
Annual total PSA screening may be reimbursable for men aged 40-50 years who are at increased risk of developing prostate cancer as determined by a physician.

ALL of the following

For individuals <76 years with total PSA <1 ng/ml and a normal DRE (if done): repeat screening at 2–4 year intervals.
For individuals <76 years with total PSA 1–3 ng/ml and a normal DRE (if done): repeat screening at 1–2 year intervals.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyProstate Specific Antigen Testing

Policy CodePolicy CPCPLAB006

Change TypeRemoved, Clarified, Revised

Effective DateSep 5, 2025

Next Review Date

Key ActionSubmit accurate documentation and claims using valid HIPAA-approved code sets; claims may be subject to review and require additional documentation upon request.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Procedure Codes and Thresholds

Procedure codes notemixed

Policy provides a non-exhaustive procedure code list; inclusion does not guarantee reimbursement.

PSA thresholds for follow-up or percent free PSA consideration

PSA thresholds for percent free PSA or follow-up testingTotal PSA >3 ng/ml for individuals <76 years OR Total PSA >4 ng/ml for individuals >75 years (per Note 1) — trigger for percent free PSA or follow-up total PSA in 6–12 months

Age-based threshold noteUse the >3 ng/ml threshold for individuals less than 76 years; use the >4 ng/ml threshold for individuals greater than 75 years

DRE as alternate triggerA very suspicious digital rectal exam (DRE) alone qualifies for percent free PSA or expedited follow-up regardless of PSA value

Follow-up timingFollow-up total PSA testing may be performed in 6–12 months when thresholds or a very suspicious DRE are met

Documentation and Claim Submission Expectations

Documentation Required

Documentation and claim submission expectations

Providers must submit accurate documentation of services performed and submit claims using valid HIPAA‑approved code sets; claims are subject to code edit protocols and may be reviewed against benefit coverage, provider contract language, medical policies, clinical payment and coding policies, and coding software logic. Upon request, providers should be prepared to submit additional documentation to support the claim.

Use valid code combinations from HIPAA‑approved code sets (CPT, HCPCS, ICD‑10, NDC, DRG guidelines, etc.).
Code claims per industry standard coding guidelines and applicable CCI/CMS edits.
Claims may be denied or adjusted after code edit or policy review; provide additional documentation when requested.

Key Terms and Definitions

Definition: 'Individuals'

Definition of 'individuals'Applies to people who have a prostate or were born with a prostate (per Note 1)

Scope implicationAll age-specific criteria and testing recommendations reference this population definition

Note linkageSee Note 1 for guidance on testing in older individuals (>75 years) and comorbidity considerations

Definition: Very suspicious digital rectal exam (DRE)

Definition of very suspicious DREA digital rectal exam (DRE) finding deemed very suspicious for prostate cancer — qualifies as a criterion for percent free PSA testing or follow-up PSA assessment

Use as triggerA very suspicious DRE alone may prompt percent free PSA testing or a 6–12 month follow-up PSA regardless of absolute PSA level

Referenced in age-based criteriaVery suspicious DRE is an alternative trigger for both individuals <76 years (with PSA>3 ng/ml) and >75 years (with PSA>4 ng/ml) per reimbursement criteria